上海药明康德新药开发有限公司 SHANGHAI PHARMATECHS CO.LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma 2024-02-20 21:00
WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site 2024-01-08 22:00
WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility 2022-09-26 20:00
WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers 2022-09-09 20:00
WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware 2022-08-17 01:47
WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility 2022-07-07 08:00
WuXi AppTec Recognized as Top-Rated ESG Company by Sustainalytics 2022-04-08 08:00
WuXi STA Wins 2022 CMO Leadership Awards in All Six Core Categories 2022-02-11 10:00
WuXi AppTec Receives AA ESG Rating from MSCI 2021-09-06 08:00
WuXi AppTec Lists H Shares on the Hong Kong Stock Exchange 2018-12-13 10:23
WuXi AppTec Appoints Edward Hu as Co-CEO 2018-08-22 18:35
WuXi AppTec Announces Listing of Initial Public Offering of Common Stock on Shanghai Stock Exchange 2018-05-08 11:44
WuXi STA Changzhou Site Passes First U.S. FDA Inspection 2018-05-07 08:00
WuXi AppTec Expands Site in the U.S. for Drug Development Testing Services 2018-04-19 11:54
1